GlassScriptPhysician profile
James B Dunaway
NPI 1699855288
$1,880.73
in general payments reported to CMS, 2019-2025
33 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $421 · 2021: $178 · 2022: $198 · 2023: $155 · 2024: $284 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.19 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $457.45 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $283.81 | 2019-2021 | |
| Abbvie INC. | $227.14 | 2019-2024 | Liletta |
| Hologic Sales and Service, LLC | $76.48 | 2022-2025 | Myosure Tissue Removal Device, Aptima |
| Organon LLC | $72.66 | 2022-2025 | Nexplanon |
| Amgen INC. | $69.63 | 2019-2024 | Evenity, Prolia |
| Exeltis, USA INC. | $53.40 | 2020-2022 | |
| Medline Industries LP | $47.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.76 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $40.48 | 2024 | |
| Myriad Women'S Health, INC. | $39.42 | 2023 | Myrisk |
| Daiichi Sankyo INC. | $36.98 | 2020-2022 | |
| Therapeuticsmd, INC. | $32.83 | 2020-2021 | |
| Biogen, INC. | $29.89 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $28.46 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $26.70 | 2024 | |
| Sumitomo Pharma America, INC. | $25.80 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $25.51 | 2019-2021 | |
| Duchesnay USA Incorporated | $24.59 | 2019 | |
| Shield Therapeutics INC | $23.77 | 2024 | |
| Roche Diagnostics Corporation | $22.41 | 2019 | |
| Novo Nordisk INC | $22.28 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $21.43 | 2025 | Caldolor |
| Smith+Nephew, INC. | $20.58 | 2025 | Pico 14 |
| Radius Health, INC. | $20.05 | 2024 | Tymlos |
| Pfizer INC. | $16.85 | 2024 | |
| Ascend Therapeutics US, LLC | $15.00 | 2020 | |
| Scynexis, INC. | $14.56 | 2022 | |
| Myovant Sciences INC. | $14.41 | 2021 | |
| Optumhealth Care Solutions, LLC | $13.85 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Glaxosmithkline, LLC. | $13.16 | 2021 | |
| Lupin INC. | $11.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dunaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.